Comparison
While AOD-9604 is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials71111115, BPC-157 is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects111.
While AOD-9604 works as a synthetic fragment of human growth hormone corresponding to residues 176–191 with an added N-terminal tyrosine, retaining lipolytic but not growth-promoting actions; proposed to stimulate lipolysis and inhibit lipogenesis in adipose tissue, partly via β3-adrenergic pathways without significantly activating the full GH receptor–IGF-1 axis6171111, BPC-157 is a synthetic 15-amino-acid fragment of a gastric cytoprotective protein that promotes angiogenesis and tissue protection primarily by modulating VEGFR2 signaling, Src/caveolin-1–dependent eNOS activation, and nitric oxide production111.
AOD-9604 is 16 amino acids long, whereas BPC-157 is shorter as it has a length of 15 amino acids. AOD-9604 is made up of a sequence of Tyrosine, Leucine, Arginine, Isoleucine, Valine, Glutamine, Cysteine, Arginine, Serine, Valine, Glutamic acid, Glycine, Serine, Cysteine, Glycine, Phenylalanine. BPC-157 is made up of a sequence of Glycine, Glutamic acid, Proline, Proline, Proline, Glycine, Lysine, Proline, Alanine, Aspartic acid, Aspartic acid, Alanine, Glycine, Leucine, Valine.
AOD-9604
BPC-157
VEGFR2 (vascular endothelial growth factor receptor 2) on endothelial cells, with downstream eNOS and nitric-oxide–mediated signaling11
AOD-9604
GH1
BPC-157
Not assigned in the current dataset.